{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:17:53Z","timestamp":1792527473719,"version":"4.5.0"},"reference-count":91,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp;amp; Cancer"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Sickle cell disease (SCD) is an inherited hemolytic hemoglobinopathy characterized by chronic hemolysis, vaso\u2010occlusive pain crises, and progressive organ damage. Hydroxyurea, often combined with analgesics, remains a mainstay therapy, but may provide insufficient relief during active disease episodes. Drug repurposing offers a practical alternative where de novo drug development is limited, providing faster and more cost\u2010effective therapeutic options. Imatinib (Gleevec), a tyrosine kinase inhibitor primarily used for chronic myeloid leukemia, has gained attention as a potential repurposed therapy for SCD. This narrative review provides a theoretical framework for evaluating imatinib's potential applications in mitigating key pathophysiological processes in SCD. Examination of the molecular pathways shared between imatinib's targets and the pathogenesis of SCD has yielded mixed findings: some studies suggest imatinib may reduce hemolysis and alleviate pain crises, while others have not supported such benefits. Direct investigations of imatinib in the context of SCD are limited, yet available evidence has reported potentially valuable outcomes, including decreased hospitalization rates, shorter hospital durations, and reduced organ damage. Current evidence remains insufficient for definitive conclusions, underscoring the need for well\u2010designed clinical and translational studies to clarify the feasibility of incorporating imatinib into SCD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Imatinib has actions on signaling pathways with potential clinical relevance to sickle cell disease, such as reduction of inflammation, vaso\u2010occlusive crises, and opioid tolerance.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Reports of use in patients with sickle cell disease suggest potential for reducing the frequency of vaso\u2010occlusive crises.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/1545-5017.70606","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:24:26Z","timestamp":1785849866000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug Repurposing in Sickle Cell Disease: Evaluating Imatinib as a Therapeutic Candidate"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3087-7650","authenticated-orcid":false,"given":"Bijan","family":"Keikhaei","sequence":"first","affiliation":[{"name":"Thalassemia &amp; Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences  Ahvaz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-2686","authenticated-orcid":false,"given":"Daryush","family":"Purrahman","sequence":"additional","affiliation":[{"name":"Thalassemia &amp; Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences  Ahvaz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-5917","authenticated-orcid":false,"given":"Najmeh","family":"Nameh Goshay Fard","sequence":"additional","affiliation":[{"name":"Thalassemia &amp; Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences  Ahvaz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0304-1452","authenticated-orcid":false,"given":"Elham","family":"Abedi","sequence":"additional","affiliation":[{"name":"Hematology Research Center Shiraz University of Medical Sciences  Shiraz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8108-9259","authenticated-orcid":false,"given":"Farnoush","family":"Farokhian","sequence":"additional","affiliation":[{"name":"Hematology Research Center Shiraz University of Medical Sciences  Shiraz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-9307","authenticated-orcid":false,"given":"Reyhane","family":"Khademi","sequence":"additional","affiliation":[{"name":"Thalassemia &amp; Hemoglobinopathy Research Center, Health Research Institute Ahvaz Jundishapur University of Medical Sciences  Ahvaz Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02160-x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17312"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijns5020020"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316672"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.01.014"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2021.03.007"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000604"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000848"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112972"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.01.003"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00118-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.05.002"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.06.001"},{"issue":"1","key":"e_1_2_10_18_1","article-title":"Are Off\u2010Target Effects of Imatinib the Key to Improving Beta\u2010Cell Function in Diabetes?","volume":"127","author":"Welsh N.","year":"2022","journal-title":"Upsala Journal of Medical Sciences"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew245"},{"issue":"3","key":"e_1_2_10_20_1","first-page":"228","article-title":"Imatinib Mesylate and Dermatology Part 2: A Review of the Cutaneous Side Effects of Imatinib Mesylate","volume":"5","author":"Scheinfeld N.","year":"2006","journal-title":"Journal of Drugs in Dermatology: JDD"},{"issue":"1","key":"e_1_2_10_21_1","first-page":"1382","article-title":"Off\u2010Target Effect of Imatinib and Nilotinib on human Vitamin D3 Metabolism","volume":"17","author":"Kroschwald L.","year":"2018","journal-title":"Molecular Medicine Reports"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1151356"},{"key":"e_1_2_10_23_1","first-page":"19","article-title":"Multiorgan Dysfunction Syndrome in Sickle Cell Disease","volume":"53","author":"Hiran S.","year":"2005","journal-title":"Journal of the Association of Physicians of India"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00673"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-135350"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.09.026"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.23029"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22140"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2023.2179484"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141206"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16671"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121596"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040610"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187511"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2025.103512"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154933"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2013.770136"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-020-01376-8"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000817"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2014.0213"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0713"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10739680802279394"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-008-0443-x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.09.019"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86249"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn352"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S148463"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2000.11746536"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-618538"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27224"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14653240902849788"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000228"},{"issue":"5","key":"e_1_2_10_53_1","first-page":"683","article-title":"Role and Significance of c\u2010KIT Receptor Tyrosine Kinase in Cancer: A Review","volume":"22","author":"Sheikh E.","year":"2022","journal-title":"Bosnian Journal of Basic Medical Sciences"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3074"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3988.3988"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202402788"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12622"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-498105"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15900"},{"issue":"4","key":"e_1_2_10_60_1","first-page":"398","article-title":"The Neuropeptide Substance p Is Elevated in Sickle Cell Disease and Is a Marker of Severity of Vaso\u2010Occlusive Crisis","volume":"65","author":"Olawuyi O. A.","year":"2024","journal-title":"Nigerian Medical Journal"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327429"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1649131"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-510982"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-198824000-00018"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703655"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000882"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13461"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-12-196"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08670.x"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2024.01.052"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.559925"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-025-04505-5"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281200"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2551"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-007-9070-6"},{"issue":"2","key":"e_1_2_10_76_1","first-page":"68","article-title":"The Effect of Celecoxib and Its Combination With Imatinib on Human HT\u201029 Colorectal Cancer Cells: Involvement of COX\u20102, Caspase\u20103, VEGF and NF\u2010\u00ce\u00b0B Genes Expression","volume":"62","author":"Atari\u2010Hajipirloo S.","year":"2016","journal-title":"Cellular and Molecular Biology"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.030"},{"issue":"4","key":"e_1_2_10_78_1","first-page":"317","article-title":"Cyclooxygenase\u20102 Induction and Prostaglandin E 2 Accumulation in Squamous Cell Carcinoma as a Consequence of Epidermal Growth Factor Receptor Activation by Imatinib Mesylate","volume":"4","author":"Johnson F. M.","year":"2004","journal-title":"Journal of Experimental Therapeutics & Oncology"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29493"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-019-0932-0"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.4196\/kjpp.2020.24.1.11"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.06.007"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2633"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00021.2018"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/272940"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2020.109197"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419603"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072276"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.018259"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.680452"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2024.11.035"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117028"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1545-5017.70606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:01:13Z","timestamp":1787670073000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1545-5017.70606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":91,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/1545-5017.70606"],"URL":"https:\/\/doi.org\/10.1002\/1545-5017.70606","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.175562135.50163879\/v1","asserted-by":"object"}]},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70606"}}